– USA, VA – Indivior PLC (LON: INDV / Nasdaq: INDV) announced the appointment of Tony Kingsley to its Board as an Independent Non-Executive Director, effective July 1, 2025.
About Tony Kingsley
Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of development and commercialization.
“Indivior has a long and successful track record of addressing the opioid use disorder with its portfolio of medicines to make meaningful recovery possible,” said Tony Kingsley. “I look forward to working closely with the Board and management team to advance Indivior’s mission and strengthen its position as a leader in delivering life-transforming treatments for opioid use disorder.”
Tony Kingsley serves as CEO and Director of Stablix, Inc., a biotechnology company pioneering deubiquitination therapeutics as a novel modality. Before joining Stablix, he was President and CEO of Scholar Rock (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases driven by protein growth factors. Previously, he served as President and CEO of TARIS Bio, guiding the company through its acquisition by Janssen Pharmaceuticals in 2019.
Earlier in his career, Tony Kingsley held a series of senior leadership roles, including President and Chief Operating Officer at The Medicines Company (Nasdaq: MDCO) and EVP of Global Commercial Operations at Biogen (Nasdaq: BIIB), where he oversaw the launch and growth of multiple therapies in neurology and hemophilia. Before this, he held numerous senior general management roles in devices and diagnostics and was a partner at McKinsey & Company.
Mr. Kingsley graduated magna cum laude from Dartmouth College and received an M.B.A. from Harvard Business School.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD, and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally, and its portfolio of products is available in over 30 countries worldwide.
For more: https://www.indivior.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.